Cytek Biosciences (CTKB) Equity Average (2020 - 2026)

Cytek Biosciences has reported Equity Average for 7 years, with the latest figure at $334.7 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 13.67% year-over-year to $334.7 million; the trailing twelve-month figure through Mar 2026 stood at $334.7 million (down 13.67% YoY), and the FY2025 full-year result was $368.7 million, down 6.51% from the prior year.
• Equity Average for Q1 2026 stood at $334.7 million, down from $360.2 million in the prior quarter.
• The five-year high for Equity Average was $424.5 million in Q1 2023, with the low at $334.7 million in Q1 2026.
• Historically, Equity Average has averaged $395.5 million across 5 years, with a median of $392.8 million in 2024.
• Annual changes were most pronounced in 2022 — Equity Average surged 8380.94% — and 2026, when it slipped 13.67%.
• Cytek Biosciences' Equity Average stood at $421.0 million in 2022, then retreated by 3.97% to $404.3 million in 2023, then slipped by 3.39% to $390.6 million in 2024, then slipped by 7.79% to $360.2 million in 2025, then fell by 7.07% to $334.7 million in 2026.
• The last three Equity Average figures came in at $334.7 million (Q1 2026), $360.2 million (Q4 2025), and $378.1 million (Q3 2025), per Business Quant data.